FDA Committee Unanimously Backs First mRNA Flu Vaccine Following Landmark Trial

In a unanimous 9-0 vote, the Food and Drug Administration’s top vaccine advisory committee has recommended the approval of the first-ever mRNA seasonal influenza vaccine.[1][6]

The investigational shot, developed by Moderna and dubbed mFlusiva (mRNA-1010), targets adults aged 50 and older. If the FDA follows the committee's recommendation by its August 5 target date, the vaccine will be available for the 2026–2027 winter flu season, marking the most significant shift in influenza prevention in decades.[2][7]

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) based its endorsement on a massive, peer-reviewed evidence base that demonstrated clear superiority over traditional flu shots.[3][6]

The primary evidence stems from the Phase 3 FLUENT trial, the results of which were published in The New England Journal of Medicine. The double-blind, active-controlled study enrolled 40,703 participants aged 50 and older, randomly assigning them to receive either the mRNA vaccine or a standard-dose, egg-based comparator.[3]

The efficacy data showed a substantial improvement. The mRNA vaccine demonstrated a 26.6% relative vaccine efficacy boost against protocol-defined, laboratory-confirmed influenza compared to the standard shot.[2][3]

More importantly for public health infrastructure, the mRNA shot reduced higher-level healthcare outcomes—including emergency room visits, urgent care visits, and hospitalizations—by 47.9%.[3][7]

The biological mechanism behind this enhanced protection appears to be a broader immune response. A separate study led by researchers at Washington University School of Medicine analyzed blood samples from trial participants.[5]

They found that the mRNA vaccine prompted the body to produce significantly more flu-specific memory B cells than standard vaccines. These cells remember past infections and can rapidly generate antibodies against a wider array of evolving influenza strains, offering a deeper layer of defense.[5]

Beyond cellular immunity, the mRNA platform solves a logistical crisis known as "strain mismatch." Traditional flu vaccines are grown in chicken eggs, a slow process that forces health officials to guess which flu strains will circulate six months before winter begins.[4][7]

If the virus mutates during that six-month window, the vaccine's effectiveness plummets—sometimes falling as low as 19% in a bad year. Because mRNA vaccines encode genetic instructions in lipid nanoparticles rather than relying on live viral growth, their manufacturing timeline is compressed to just two to three months.[4][5]

However, the evidence pack also highlights a clear trade-off: reactogenicity. The mRNA vaccine triggers a noticeably stronger temporary physical reaction than traditional flu shots.[3][4]

According to the clinical data, 65.8% of mRNA recipients reported injection-site pain, compared to 29.8% in the standard group. Fatigue affected 45.1% of mRNA recipients versus 20.3% of the control group, and headaches were reported by 37.8% compared to 18.0%.[3]

Despite the higher rate of these mild-to-moderate side effects, the safety profile remains robust. Serious adverse events were exceedingly rare and statistically identical between the two groups, occurring in 2.2% of mRNA recipients and 1.9% of those receiving the standard dose.[3][4]

The unanimous committee vote represents a dramatic regulatory turnaround. In February 2026, the FDA initially refused to review Moderna's application, with officials arguing the company should have tested the shot against a high-dose comparator specifically designed for seniors, rather than a standard dose.[2][6]

Following public pushback and a formal meeting, the agency reversed course days later, agreeing to review the data differentially for the 50-to-64 and 65-and-older age brackets.[2][7]

To address lingering evidentiary gaps regarding the frailest patients, the FDA is requiring a massive post-marketing confirmatory trial. If granted accelerated approval for the 65-and-older cohort, Moderna will enroll up to 400,000 seniors over two flu seasons to directly compare the mRNA shot against existing high-dose senior vaccines.[2][6]

As the August decision date approaches, the medical consensus is clear: the mRNA technology that altered the trajectory of the COVID-19 pandemic has successfully crossed over to seasonal respiratory viruses.[1][7]